Designing Safer Cannabinoid Pharmacotherapies - Med-Cann World - Video
And now for the other side of the coin: like any medication, over-exposure to medical cannabis can cause unwanted side effects and we as professionals must not be blind to the risks. In this panel, Steven Laviolette (Professor and Neuroscientist at the Schulich School of Medicine & Dentistry - Western University) reminds us of the dangers of unregulated usage. “What we find typically is that with Chronic THC Exposure you can get things like increased anxiety, cognitive problems, depression and Schizophrenia-like symptoms.”
Video Presentation by Dr. Steven Laviolette
Dr. Steven Laviolette is a Professor and Neuroscientist in the Schulich School of Medicine &. Dentistry at Western University in London. Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded 'Faculty Scholar' status at Western University. Dr. Laviolette's research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette's primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette's team has been published in the top tier of neuroscience and psychiatry journals in the world. CanaQuest Medical Corporation is the industry partner for research and product development with Dr. Laviolette. CanaQuest is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade).
Customer comments
No comments were found for Designing Safer Cannabinoid Pharmacotherapies - Med-Cann World - Video. Be the first to comment!